cfDNA dynamics decipher mechanism of action of Ibrutinib in patients with MCL
We investigated cfDNA dynamics prior to and during induction treatment of patients with MCL treated within the TRIANGLE trial and showed an early and superior disease clearance when treated with Ibrutinib and hints toward improved disease clearance in lymph nodes than using chemotherapy